BioCryst Pharmaceuticals
BCRX
BCRX
257 hedge funds and large institutions have $1.32B invested in BioCryst Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 80 increasing their positions, 74 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
8% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 74
0.82% less ownership
Funds ownership: 84.49% → 83.67% (-0.82%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
257
Holding in Top 10
4
Calls
$12.6M
Puts
$6.43M
Top Buyers
| 1 | +$11.7M | |
| 2 | +$8.13M | |
| 3 | +$7.29M | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.86M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$6.66M |
Top Sellers
| 1 | -$15.3M | |
| 2 | -$8.95M | |
| 3 | -$7.15M | |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$6.87M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$6.76M |